

4 year surveillance (2017) – [Hepatitis B \(chronic\) : diagnosis and management \(2013\) NICE guideline CG165](#)

Stakeholder consultation comments form - proposal for 'no update'

Consultation on the proposal for 'no update' opens on: 19 July 2017
Comments on proposal to be submitted: no later than 9am 2 August 2017

<p>Please enter the name of your registered stakeholder or respondent organisation below.</p> <p>Please use this form for submitting your comments to NICE.</p> <ol style="list-style-type: none"> Please put each new comment in a new row. Please note – we cannot accept comments forms with attachments such as research articles, letters or leaflets. If we receive forms with attachments we will return them without reading the comments. If you resubmit the comments on a form without attachments, this must be by the consultation deadline. If you wish to draw our attention to published studies, please supply the full reference. NICE is unable to accept comments from non-registered organisations. If you wish your comments to be considered please register via the NICE website or contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. 	
<p>Organisation name – Stakeholder or respondent (if you are commenting as an individual rather than a registered stakeholder or respondent organisation, please leave blank):</p>	<p>BHIVA/BASHH Consultation Group on Hepatitis Topics, representing the British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASHH)</p>
<p>Disclosure Please disclose whether the organisation has any past or current, direct or indirect links to, or receives funding from, the tobacco industry.</p>	<p>None</p>
<p>Name of commentator:</p>	<p>Dr S Bhagani, on behalf of the BHIVA/BASHH Consultation Group on Hepatitis Topics</p>

[Developing NICE guidelines: the manual](#) gives an overview of the processes used in surveillance reviews of NICE clinical guidelines.

ID	Questions	Overall response yes / no	Comments Please insert each new comment in a new row
1	Do you agree with the proposal not to update the guideline?	No	We are disappointed to learn that NICE has decided not to review/update CG165, published in 2013.
			<p>There have been a number of important innovations/changes since this guidance that will impact patient care in England and Wales:</p> <ul style="list-style-type: none"> a) Publication of the WHO targets for reduction in new incidence and mortality for HBV and HCV b) Update of EASL, AASLD Hep B guidelines and publication of the WHO guidance on the diagnosis, assessment and management of HBV c) More data on the efficacy (or lack of) and HBsAg and HBV DNA based stopping rules for the use of Peg-IFN-alpha d) More data on finite therapy with nucleos(t)ides e) Approval of Tenofovir-Alafenimide (TAF) for the treatment of HBV f) Data on the use of oral antivirals to prevent mother-to-child transmission of HBV g) Data on the risk of HBV re-activation post successful HCV treatment in co-infected patients h) Roll-out of TDF/FTC for HIV post-exposure prophylaxis, and the need for HBV testing in 'at risk' groups AND the need to avoid TDF 'mono-therapy' for the treatment of chronic HBV in patients also requiring HIV pre-exposure prophylaxis
			We urge the committee to reconsider this decision. The current guidance, unfortunately, provides for sub-standard care in this highly vulnerable group of patients.
2	Do you agree with the proposal to remove the research recommendation: RR – 01 To evaluate the clinical and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in hepatitis B e antigen		

ID	Questions	Overall response yes / no	Comments Please insert each new comment in a new row
	(HBeAg) negative disease.		
3	<p>Do you agree with the proposal to remove the research recommendation: RR – 02 To examine whether the upper limit of normal ALT values for adults (below 30 IU/L for males and below 19 IU/L for females) are appropriate for use in children and young people with chronic hepatitis B when making decisions on when to initiate treatment.</p>		
4	<p>Do you agree with the proposal to remove the research recommendation: RR – 04 To determine whether long-term use of mild immunosuppressive agents for autoimmune and allergic problems presents a risk for reactivation of HBV infection in people with previous or current chronic hepatitis B, including occult HBV infection. The cost effectiveness of routine tests for HBV in this population, including HBV DNA for occult HBV infection, and the need for prophylactic treatment with nucleoside or nucleotide analogues needs further evaluation.</p>		
5	Do you have any comments on areas excluded from the scope of the guideline?		
6	Do you have any comments on equalities issues?		

Please email this form to: surveillance@nice.org.uk

Closing date: 2 August 2017

PLEASE NOTE:

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE's reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.